China Spurns 30 Drug Apps Due to Fudged Data

BEIJING, Oct. 22 (Xinhua) -- China's drug safety watchdog has rejected 30 new drug registration applications due to fabrication of clinical trial data, it said.

"As of the end of September, 117 registration applications had been verified, 30 of which were rejected due to defects with authenticity, accounting for about 2 percent of the total registration applications for self-examination and verification," an official with the China Food and Drug Administration (CFDA) told Xinhua Friday.

In addition, 27 applications, 11 clinical trial institutions and Contract Research Organizations suspected of providing fraudulent data have been investigated since the CFDA organized the verification for registration applications under review in October 2015, the official said.
MORE ON THIS TOPIC